Is AMLX or IMVT more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Immunovant N/A -65.66% -59.88%

Does the media favor AMLX or IMVT?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 5 mentions for Immunovant. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat Immunovant's score of 1.05 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AMLX or PCVX more profitable?

Vaxcyte's return on equity of -32.51% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Vaxcyte N/A -32.51% -29.51%

Does the media favor AMLX or PCVX?

In the previous week, Vaxcyte had 13 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Vaxcyte and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat Vaxcyte's score of 0.95 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMLX or IBRX?

In the previous week, ImmunityBio had 6 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 12 mentions for ImmunityBio and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat ImmunityBio's score of 0.56 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or AMLX?

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Amylyx Pharmaceuticals' score of 1.09 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or AMLX?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Amylyx Pharmaceuticals' score of 1.09 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$20.31 -0.44 (-2.12%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$19.75 -0.56 (-2.76%)

As of 07/31/2026 07:34 PM Eastern

Compare

AMLX vs. IMVT, PCVX, IBRX, RYTM, and MIRM

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Amylyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amylyx Pharmaceuticals include Immunovant (IMVT), Vaxcyte (PCVX), ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM).

How does Amylyx Pharmaceuticals compare to Immunovant?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 5 mentions for Immunovant. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat Immunovant's score of 1.05 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals currently has a consensus price target of $24.63, indicating a potential upside of 21.25%. Immunovant has a consensus price target of $42.11, indicating a potential upside of 9.04%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Amylyx Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Amylyx Pharmaceuticals' return on equity of -55.69% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Immunovant	N/A	-65.66%	-59.88%

Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Immunovant on 14 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Amylyx Pharmaceuticals has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Amylyx Pharmaceuticals currently has a consensus target price of $24.63, suggesting a potential upside of 21.25%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 59.02%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Vaxcyte's return on equity of -32.51% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Vaxcyte	N/A	-32.51%	-29.51%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Vaxcyte had 13 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Vaxcyte and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat Vaxcyte's score of 0.95 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has higher revenue and earnings than Vaxcyte. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Amylyx Pharmaceuticals beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to ImmunityBio?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Amylyx Pharmaceuticals currently has a consensus target price of $24.63, indicating a potential upside of 21.25%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 98.05%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Amylyx Pharmaceuticals has higher earnings, but lower revenue than ImmunityBio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A
ImmunityBio	$113.29M	66.29	-$351.40M	-$0.85	N/A

Amylyx Pharmaceuticals has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
ImmunityBio	-606.15%	N/A	-59.53%

In the previous week, ImmunityBio had 6 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 12 mentions for ImmunityBio and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.09 beat ImmunityBio's score of 0.56 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ImmunityBio beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Amylyx Pharmaceuticals' score of 1.09 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	10 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals presently has a consensus price target of $138.73, indicating a potential upside of 39.78%. Amylyx Pharmaceuticals has a consensus price target of $24.63, indicating a potential upside of 21.25%. Given Rhythm Pharmaceuticals' higher probable upside, research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.84	-$196.54M	-$3.13	N/A
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Amylyx Pharmaceuticals' score of 1.09 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $143.40, indicating a potential upside of 35.35%. Amylyx Pharmaceuticals has a consensus target price of $24.63, indicating a potential upside of 21.25%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.39	-$23.36M	-$13.61	N/A
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A

Summary

Mirum Pharmaceuticals beats Amylyx Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.26B	$3.55B	$7.17B	$12.47B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-13.54	4.31	222.53	22.11
Price / Sales	25.85	1,250.60	584.70	90.03
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	7.31	16.78	10.93	6.07
Net Income	-$144.74M	-$12.56M	$3.50B	$348.34M
7 Day Performance	10.32%	-1.47%	-0.24%	0.09%
1 Month Performance	11.17%	-8.45%	-3.70%	-5.17%
1 Year Performance	163.08%	48.32%	61.98%	18.61%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	3.6394 of 5 stars	$20.31 -2.1%	$24.63 +21.2%	+163.1%	$2.26B	$87.37M	N/A	200	News Coverage Positive News Upcoming Earnings
IMVT Immunovant	1.8784 of 5 stars	$40.09 +1.7%	$42.11 +5.0%	+145.8%	$8.13B	N/A	N/A	120	Positive News Upcoming Earnings
PCVX Vaxcyte	2.7511 of 5 stars	$55.50 +1.5%	$86.00 +55.0%	+63.8%	$7.89B	N/A	N/A	160	News Coverage Positive News Upcoming Earnings Insider Trade
IBRX ImmunityBio	2.5394 of 5 stars	$6.99 -1.5%	$14.20 +103.1%	+202.5%	$7.44B	$113.29M	N/A	590	News Coverage Positive News Upcoming Earnings
RYTM Rhythm Pharmaceuticals	3.3904 of 5 stars	$106.13 +3.9%	$138.73 +30.7%	+12.4%	$7.00B	$189.76M	N/A	140	News Coverage Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IMVT, PCVX, IBRX, RYTM, and MIRM

How does Amylyx Pharmaceuticals compare to Immunovant?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Summary

How does Amylyx Pharmaceuticals compare to ImmunityBio?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IMVT, PCVX, IBRX, RYTM, and MIRM

How does Amylyx Pharmaceuticals compare to Immunovant?

Does the media favor AMLX or IMVT?

Do analysts recommend AMLX or IMVT?

Do institutionals & insiders have more ownership in AMLX or IMVT?

Which has better valuation & earnings, AMLX or IMVT?

Is AMLX or IMVT more profitable?

Which has more volatility & risk, AMLX or IMVT?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Which has more volatility & risk, AMLX or PCVX?

Do analysts prefer AMLX or PCVX?

Is AMLX or PCVX more profitable?

Do institutionals & insiders hold more shares of AMLX or PCVX?

Does the media favor AMLX or PCVX?

Which has higher valuation & earnings, AMLX or PCVX?

Summary

How does Amylyx Pharmaceuticals compare to ImmunityBio?

Do analysts rate AMLX or IBRX?

Which has more volatility & risk, AMLX or IBRX?

Which has preferable earnings and valuation, AMLX or IBRX?

Is AMLX or IBRX more profitable?

Does the media prefer AMLX or IBRX?

Do insiders and institutionals believe in AMLX or IBRX?

Summary

How does Amylyx Pharmaceuticals compare to Rhythm Pharmaceuticals?

Is RYTM or AMLX more profitable?

Do institutionals & insiders believe in RYTM or AMLX?

Does the media prefer RYTM or AMLX?

Do analysts prefer RYTM or AMLX?

Which has preferable valuation & earnings, RYTM or AMLX?

Which has more volatility & risk, RYTM or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or AMLX more profitable?

Does the media refer more to MIRM or AMLX?

Which has more risk & volatility, MIRM or AMLX?

Do analysts recommend MIRM or AMLX?

Do insiders & institutionals have more ownership in MIRM or AMLX?

Which has preferable valuation & earnings, MIRM or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools